TFF Pharmaceuticals, Inc.

Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded. I will now turn the call over to our host, Corey Davis of LifeSciAdvisors. You may begin your conference.

Thank you, Operator. Hello, everyone, and welcome to TFF Pharmaceuticals' third quarter 2023 Corporate Update and Earnings Conference Call. With me on the line this afternoon are Dr. Harlan Weissman, Chief Executive Officer of TFF Pharmaceuticals, Dr. Zamaneh Mekak, Chief Medical Officer, and Kirk Coleman, Chief Financial Officer. Before we get started, I'd like to remind everyone that this call will contain forward-looking statements, including, without limitation, statements about the anticipated timing of achievement of clinical milestones. the potential to see positive effects in our Phase II studies, a number of treated patients necessary to make decisions in regards to moving to Phase III studies, the market opportunity for our product candidates, and the expected timeframe for funding operations with cash and cash equivalents. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in all of our filings with the U.S. Securities and Exchange Commission, including the Risk Factors section of our 2022 Annual Report on Form 10-K filed with the SEC. Now it's my pleasure to turn the call over to Dr. Harlan Weissman.

Go ahead, Harlan.